BioInvent International AB (publ) (BINV.ST)

31,75 -1,75 (-5,22%) A partir del 11:28AM CEST. Mercado abierto.

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 109

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Martin Welschof Ph.D.	President & CEO	5,17M	N/A	1961
Mr. Stefan Ericsson M.B.A.	Chief Financial Officer	N/A	N/A	1963
Ms. Marie Moores M.Sc., R.G.N.	Chief Operating Officer	N/A	N/A	N/A
Mr. Kristoffer Rudenholm Hansson	Senior Vice President of Technical Operations	N/A	N/A	1974
Mr. Björn Frendéus	Chief Scientific Officer	2,35M	N/A	1973
Ms. Cecilia Hofvander	Senior Director of Investor Relations	N/A	N/A	1967
Dr. Andres McAllister	Chief Medical Officer	N/A	N/A	1956
Ms. Ingrid Teige	Head of Preclinical Research	N/A	N/A	N/A
Ms. Sylvie Ryckebusch	Chief Business Officer	N/A	N/A	N/A
Dr. Ingunn Munch Lindvig	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en SEK.

Descripción

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.

Gobierno corporativo

El ISS Governance QualityScore de BioInvent International AB (publ), a día 1 de junio de 2024, es 4. Las puntuaciones base son Auditoría: 9; Tablero: 1; Derechos de los accionistas: 1; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.